At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 299 enrolled
Drug / intervention
Rifaximin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID For 6 Months In Preventing Hepatic Encephalopathy
In Brief
A Phase 3 clinical trial evaluating Rifaximin and Placebo for Hepatic Encephalopathy. Completed, enrolled 299 participants.
Detailed Summary
The purpose of this study is to determine if the study drug is safe and effective in preventing hepatic encephalopathy (HE).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Encephalopathy
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2005
First PostedMar 2006
Primary CompletionAug 2008
TodayJul 2026
First PostedMar 1, 2006
Enrollment StartDec 19, 2005
Primary CompletionAug 15, 2008
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 20.3 years ago
Interventions
Rifaximindrug
Oral
Placebodrug
Oral